Effects of dapagliflozin on myocardial motion parameters and cardiac electrophysiology in patients with type 2 diabetes Mellitus and coronary heart disease
Fang Liu, Rui Jin · 2026
Read Effects of dapagliflozin on myocardial motion parameters and cardiac electrophysiology in patients with type 2 diabetes Mellitus and coronary heart disease by Fang Liu, Rui Jin (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13275283.txt.
Description
Fang Liu and Rui Jin studied dapagliflozin in patients with both type 2 diabetes and coronary heart disease in a 2026 retrospective study. The two diseases feed each other and damage heart function together. This diabetes drug has shown heart benefits elsewhere, and the team tested its effect on heart motion and electrical activity.
They compared 125 patients who received dapagliflozin on top of standard care with 137 on standard care plus metformin, over four weeks in one hospital's records. The drug group improved more in pumping strength, muscle strain and work measures, and exercise tolerance, with a higher rated success rate. Electrical measures also shifted favorably, including longer recovery intervals and less ST depression. Adverse heart event rates did not differ. The authors support adding the drug in this combined condition.
Catalog record
| CREATOR | Fang Liu, Rui Jin |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 37 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |